Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.

Sabina DavidssonAnna Messing ErikssonRuzan UdumyanPer SwanholmMaria Lewin LundhCarolina WidingChristina LindlöfJonna FridfeldtSven-Olof AnderssonKatja Fall

Published in: The Prostate (2023)

Our results do not support the hypothesis that ADT use in prostate cancer patients reduces the risk or symptom severity of SARS-CoV-2 infection or that prostate cancer patients are at increased risk of COVID-19 compared with men without prostate cancer.

Keyphrases

prostate cancer
radical prostatectomy
coronavirus disease
sars cov
middle aged
respiratory syndrome coronavirus
stem cells
benign prostatic hyperplasia
mesenchymal stem cells
patient reported
replacement therapy